What is alveolar rhabdomyosarcoma?
Alveolar rhabdomyosarcoma (ARMS) is a fast-growing cancer of the soft tissues. It belongs to the rhabdomyosarcoma family, the commonest group of soft-tissue cancers in children.
Rhabdomyosarcomas start from immature cells that would normally develop into skeletal (voluntary) muscle. Despite this, they can grow almost anywhere in the body, including places with little muscle, such as the nose or the bladder.
The word “alveolar” describes how the cells look under the microscope. They form small clusters separated by thin walls, a pattern that resembles the tiny air sacs (alveoli) of the lung. The cancer has nothing to do with the lungs.
ARMS mainly affects older children, teenagers and young adults. It most often starts in the arms, legs, trunk or the area around the anus and genitals.
Most cases carry a typical gene change, a fusion between the PAX3 or PAX7 gene and the FOXO1 gene. Doctors now use this fusion, rather than the microscope pattern alone, to decide how intensive treatment needs to be.
ARMS is treated with a combination of chemotherapy, surgery and radiotherapy. Many young people with localised disease are cured, but the outlook is harder when the cancer has spread.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Soft-tissue sarcoma; a subtype of rhabdomyosarcoma |
| How common | About 20-30% of all rhabdomyosarcomas; rhabdomyosarcoma as a whole affects about 4-5 children per million each year |
| Typical age | Any age, but mostly 10-25 years; also seen in infants and adults |
| Sex | Boys and girls are affected about equally |
| Main sites | Arms and legs (including hands and feet), trunk, perineum and perianal area, paraspinal area, head and neck |
| Key gene change | PAX3::FOXO1 or PAX7::FOXO1 fusion in about 80% |
| Spread | Lymph nodes, bone marrow, bones and lungs |
| Main treatments | Multi-drug chemotherapy, surgery, radiotherapy, maintenance chemotherapy |
| Outlook | Roughly 50-65% long-term survival for localised disease; much lower when it has spread at diagnosis |
2. Types and related tumours
The World Health Organization (WHO) recognises four main types of rhabdomyosarcoma. ARMS is the second most common after the embryonal type.
| Type | Who it affects | Typical features |
|---|---|---|
| Embryonal | Mostly children under 10 | Commonest type; head and neck, bladder, prostate; usually no gene fusion |
| Alveolar | Older children, teenagers, young adults | Limbs, trunk, perineum; PAX::FOXO1 fusion in most; more likely to spread |
| Spindle cell / sclerosing | Infants and adults | Some carry MYOD1 mutations or VGLL2/NCOA2 fusions |
| Pleomorphic | Older adults | Large, very abnormal cells; usually in the thigh |
Within ARMS, doctors distinguish two groups by genetic testing:
| Group | Share of ARMS | What it means |
|---|---|---|
| Fusion-positive, PAX3::FOXO1 | About 60% | The most aggressive form, especially when it has spread |
| Fusion-positive, PAX7::FOXO1 | About 20% | Often in younger patients; somewhat better outlook than PAX3 |
| Fusion-negative | About 20% | Behaves much like embryonal rhabdomyosarcoma and is treated like it |
3. Causes and risk factors
In almost everyone with ARMS, there is no known cause. It is not caused by injury, diet or anything a parent did or did not do.
The cancer develops when two chromosomes break and rejoin in the wrong way inside a single cell. This joins part of the PAX3 (chromosome 2) or PAX7 (chromosome 1) gene to the FOXO1 gene on chromosome 13.
The new fusion protein switches on genes that keep the cell in an immature, rapidly dividing state. It also helps the cells move and spread.
| Factor | Notes |
|---|---|
| Acquired gene fusion | Found only in the tumour, not in the rest of the body, and not passed on to children |
| Inherited syndromes | Li-Fraumeni syndrome, neurofibromatosis type 1, Costello and Noonan syndromes and DICER1 syndrome raise the risk of rhabdomyosarcoma, mainly the embryonal type |
| Family history | Most families have no history of cancer; genetic counselling is offered if there are other cancers in the family |
| Environment | No clear environmental cause has been proven |
4. How does it look?
4.1 On the body
| Feature | What it looks or feels like |
|---|---|
| Lump | A firm, deep swelling in the arm, leg, hand, foot, buttock or trunk, often painless at first |
| Growth | Gets bigger over weeks rather than months |
| Skin | Usually normal over the lump; it may look stretched, shiny or bluish when the tumour is large |
| Perineum | A lump near the anus, scrotum or vulva that may be mistaken for an abscess or hernia |
| Lymph nodes | Firm, enlarged glands in the groin, armpit or neck |
| Face and eye | Swelling of the cheek or eyelid, or an eye that bulges forward, when the tumour is in the head and neck |
4.2 On scans
| Test | Typical findings |
|---|---|
| Ultrasound | A solid mass with a good blood supply; often the first test for a new lump |
| MRI | The best way to see the tumour and how far it reaches into muscle, bone, nerves and vessels; bright on T2 images and enhancing after contrast |
| CT of the chest | Looks for small spots of spread in the lungs |
| PET-CT | Shows active disease in lymph nodes, bone and bone marrow; helpful because ARMS often spreads to these areas |
4.3 Under the microscope
| Feature | What the pathologist sees |
|---|---|
| Pattern | Nests of small, round, blue cells separated by thin fibrous walls; the cells in the middle fall apart, leaving spaces like alveoli |
| Solid variant | Sheets of cells without the alveolar spaces; still counted as ARMS |
| Muscle markers | Strong staining for myogenin and desmin, and for MyoD1 |
| Giant cells | Large cells with several nuclei arranged in a ring may be present |
| Genetic test | FISH, RT-PCR or sequencing shows the PAX3::FOXO1 or PAX7::FOXO1 fusion |
5. Symptoms
The symptoms depend on where the tumour grows. Many children feel well at first, and the only sign is a lump that keeps growing.
5.1 Symptoms by site
| Site | Common symptoms |
|---|---|
| Arm, leg, hand or foot | Growing lump, aching or pain, stiffness, limp or reduced use of the limb |
| Trunk or back | Lump in the chest wall or back; back pain; weakness or numbness if the spine is pressed |
| Perineum or perianal area | Lump, pain on sitting, constipation or problems passing urine |
| Head and neck | Blocked nose, nosebleeds, ear discharge, facial swelling, double vision or a bulging eye |
| Lymph nodes | Painless, firm swelling in the groin, armpit or neck |
5.2 Symptoms of spread
| Area | Possible symptoms |
|---|---|
| Bone marrow | Tiredness, pale skin, bruising and infections due to low blood counts |
| Bones | Bone pain, sometimes at night, or a fracture after minor injury |
| Lungs | Cough or breathlessness, though lung spots often cause no symptoms |
| General | Weight loss, fever or feeling generally unwell |
5.3 When to see a doctor
See a doctor if a lump:
- Is larger than about 5 cm (the size of a golf ball)
- Keeps growing over two to four weeks
- Is deep in the muscle rather than just under the skin
- Comes back after it has been removed
- Is painful without an obvious injury
Most lumps in children are harmless, but a deep, growing lump needs an urgent scan and, if needed, a biopsy at a specialist sarcoma or children’s cancer centre.
6. Diagnosis
A biopsy is the only way to confirm ARMS. It should be planned by the team who will treat the child, so that the biopsy track can be removed later if surgery is needed.
| Test | Why it is done |
|---|---|
| Core needle or open biopsy | Confirms the diagnosis and provides tissue for genetic tests |
| Fusion testing (FISH, RT-PCR or sequencing) | Shows whether the tumour is PAX3- or PAX7-fusion-positive, which guides risk group and treatment |
| MRI of the primary site | Shows tumour size and its relation to nearby structures |
| CT chest | Looks for lung spread |
| PET-CT or bone scan | Looks for spread to lymph nodes and bone |
| Bone marrow aspirate and biopsy | Checks for marrow involvement, which is relatively common in ARMS |
| Lymph node sampling | Recommended for tumours of the arms and legs, where node spread is common even when nodes look normal |
| Blood tests | Blood count, kidney and liver function before chemotherapy |
| Heart and hearing tests | Baseline before drugs that can affect the heart or kidneys |
7. Staging and risk groups
Doctors combine several pieces of information to place each patient in a risk group. This decides the intensity and length of treatment.
| Factor | What is assessed |
|---|---|
| Fusion status | Fusion-positive tumours need more intensive treatment than fusion-negative ones |
| Site | Favourable sites include the orbit, non-parameningeal head and neck and some genitourinary sites; limbs and trunk are unfavourable |
| Size | Tumours over 5 cm carry a higher risk |
| Lymph nodes | Node involvement raises the risk group |
| Surgery result | Whether the tumour was completely removed before chemotherapy (IRS clinical group) |
| Distant spread | Spread to lungs, bone, marrow or distant nodes means high-risk or very-high-risk disease |
| Age | Children under 1 year and adults tend to do less well |
Most patients with fusion-positive ARMS fall into the intermediate-risk or high-risk groups.
8. Treatment
Treatment is given at a specialist children’s or sarcoma centre, often as part of a clinical trial. It usually lasts about 9-12 months and combines three approaches.
8.1 Chemotherapy
| Phase | What it involves |
|---|---|
| Induction | Several drugs given in cycles every three weeks. In North America the backbone is VAC (vincristine, actinomycin D, cyclophosphamide); in Europe it is IVA (ifosfamide, vincristine, actinomycin D), sometimes with doxorubicin |
| Local treatment | Surgery and/or radiotherapy, usually after about 9-12 weeks of chemotherapy |
| Further cycles | Chemotherapy continues after local treatment |
| Maintenance | Six months of low-dose oral cyclophosphamide with weekly intravenous vinorelbine improved survival in high-risk rhabdomyosarcoma in the European RMS 2005 trial |
8.2 Surgery and radiotherapy
| Treatment | When it is used | Notes |
|---|---|---|
| Surgery | When the tumour can be removed completely without serious loss of function | Removal of affected lymph nodes may be added |
| Radiotherapy | For almost all fusion-positive tumours, and when surgery would leave tumour behind or cause disability | Typical doses are about 41-50 Gy; proton therapy may be used to spare growing tissues |
| Treatment of metastases | Radiotherapy to sites of spread where possible | Part of the plan for high-risk disease |
8.3 If the cancer comes back
| Option | Notes |
|---|---|
| Second-line chemotherapy | Combinations such as vincristine with irinotecan and temozolomide, or ifosfamide-based regimens |
| Further surgery or radiotherapy | For a single site of relapse |
| Clinical trials | New drugs, immunotherapy and targeted treatments are being tested |
9. Side effects and late effects
Treatment is intensive, and side effects are expected. The team gives medicines to prevent sickness and treats infections quickly.
| Effect | Cause | What helps |
|---|---|---|
| Low blood counts and infections | Chemotherapy | Blood tests, prompt antibiotics for fever, transfusions |
| Nerve tingling, constipation | Vincristine | Laxatives, dose adjustment |
| Bladder irritation | Cyclophosphamide and ifosfamide | Fluids and the protective drug mesna |
| Kidney problems | Ifosfamide | Regular kidney tests |
| Liver problems | Actinomycin D | Liver tests; rarely a serious liver condition (veno-occlusive disease) |
| Fertility | Alkylating drugs and pelvic radiotherapy | Sperm or egg/ovarian tissue storage before treatment where possible |
| Growth and bone changes | Radiotherapy to growing tissues | Physiotherapy, orthopaedic follow-up |
| Second cancers | Chemotherapy and radiotherapy | Lifelong follow-up |
10. Outlook
The outlook depends mainly on whether the cancer has spread, the fusion status and the site.
| Situation | Approximate long-term survival |
|---|---|
| Localised, fusion-negative | Similar to embryonal rhabdomyosarcoma; most are cured |
| Localised, fusion-positive | About 50-65% |
| Metastatic, fusion-negative | About 40-50% |
| Metastatic, fusion-positive | Under 20-30%; poorest when there are several sites of spread or bone marrow involvement |
| Relapsed disease | Often difficult to cure, especially after intensive first treatment |
Numbers come from large groups of patients treated in the past. They cannot predict what will happen to any one person, and results continue to improve with new trials.
11. Follow-up and living with ARMS
After treatment, children and young adults have regular check-ups with scans for several years. Visits become less frequent with time.
| Time after treatment | Typical follow-up |
|---|---|
| Years 1-2 | Clinic visit and scans of the original site and chest every 3-4 months |
| Years 3-5 | Visits every 4-6 months |
| After 5 years | Yearly review in a long-term follow-up clinic, with checks on growth, heart, kidneys, hearing, hormones and fertility |
Practical support matters too. Teenagers and young adults may benefit from specialist teenage and young adult (TYA) services, help with school or work, and psychological support for the whole family.
12. Frequently asked questions
| Question | Answer |
|---|---|
| Is alveolar rhabdomyosarcoma inherited? | Usually not. The gene fusion arises only in the tumour cells |
| Why is the fusion test so important? | Fusion-positive tumours behave more aggressively and need more intensive treatment, while fusion-negative ones are treated like embryonal rhabdomyosarcoma |
| Can adults get it? | Yes. Adults are treated with the same type of regimens, ideally at a sarcoma centre with links to children’s oncology |
| Will my child lose their hair? | Most chemotherapy for ARMS causes temporary hair loss; hair grows back after treatment |
| Can my child go to school? | Often yes, between treatments, when blood counts are safe; the team will advise |
Resources
- WHO Classification of Tumours Editorial Board (2020) Soft Tissue and Bone Tumours. 5th edn. Lyon: International Agency for Research on Cancer.
- Skapek, S.X. et al. (2019) ‘Rhabdomyosarcoma’, Nature Reviews Disease Primers, 5(1), p. 1.
- Sorensen, P.H. et al. (2002) ‘PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children’s Oncology Group’, Journal of Clinical Oncology, 20(11), pp. 2672-2679.
- Missiaglia, E. et al. (2012) ‘PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification’, Journal of Clinical Oncology, 30(14), pp. 1670-1677.
- Skapek, S.X. et al. (2013) ‘PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a Children’s Oncology Group report’, Pediatric Blood & Cancer, 60(9), pp. 1411-1417.
- Sultan, I. et al. (2009) ‘Comparing adult and pediatric rhabdomyosarcoma in the Surveillance, Epidemiology and End Results program, 1973 to 2005: an analysis of 2,600 patients’, Journal of Clinical Oncology, 27(20), pp. 3391-3397.
- Hawkins, D.S. et al. (2018) ‘Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the Children’s Oncology Group’, Journal of Clinical Oncology, 36(27), pp. 2770-2777.
- Bisogno, G. et al. (2019) ‘Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial’, The Lancet Oncology, 20(11), pp. 1566-1575.
- National Cancer Institute (2026) Childhood Rhabdomyosarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/rhabdomyosarcoma-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.